Why the study?
Does enhanced skeletal muscle expression of EcSOD mitigate streptozotocin-induced diabetic cardiomyopathy?
Does enhanced skeletal muscle expression of EcSOD mitigate streptozotocin-induced diabetic cardiomyopathy?
Enhanced skeletal muscle expression of EcSOD mitigates diabetic cardiomyopathy, suggesting a cross-organ mechanism for the cardiovascular benefits of exercise in diabetes.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for muscle-derived EcSOD therapies in diabetic cardiomyopathy; extends exercise benefit mechanisms but requires human validation.
Enhanced expression of EcSOD in skeletal muscle is sufficient to mitigate streptozotocin-induced diabetic cardiomyopathy through attenuation of oxidative stress, aberrant cell signaling, and inflammation, suggesting a cross-organ mechanism by which exercise training improves cardiac function in diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Call et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: